Matthew Kaplan

Stock Analyst at Ladenburg Thalmann

(2.82)
# 1,947
Out of 5,105 analysts
26
Total ratings
62.5%
Success rate
19%
Average return

Stocks Rated by Matthew Kaplan

United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $319$344
Current: $493.99
Upside: -30.36%
UroGen Pharma
Jun 14, 2024
Maintains: Buy
Price Target: $48$54
Current: $21.80
Upside: +145.41%
TG Therapeutics
May 2, 2024
Maintains: Buy
Price Target: $39$40
Current: $31.35
Upside: +27.59%
Liquidia
Dec 21, 2023
Maintains: Buy
Price Target: $15$30
Current: $33.38
Upside: -10.13%
Ardelyx
Aug 3, 2023
Maintains: Buy
Price Target: $7.5$8.5
Current: $6.21
Upside: +36.88%
Avadel Pharmaceuticals
May 2, 2023
Maintains: Buy
Price Target: $15$16
Current: $21.36
Upside: -25.09%
Kiora Pharmaceuticals
Feb 8, 2023
Reiterates: Buy
Price Target: $1,071
Current: $2.14
Upside: +50,063.93%
Beyond Air
Jun 29, 2022
Maintains: Buy
Price Target: $340$460
Current: $1.06
Upside: +43,296.23%
Lipocine
Dec 10, 2020
Upgrades: Buy
Price Target: $51
Current: $3.17
Upside: +1,508.83%
Cogent Biosciences
Oct 14, 2020
Initiates: Buy
Price Target: $16
Current: $42.11
Upside: -62.00%
Initiates: Buy
Price Target: $45
Current: $5.70
Upside: +689.47%